Chinese approval boosts Revlimid's long-term prospects
This article was originally published in Scrip
Executive Summary
Celgene's Revlimid (lenalidomide) has been approved in China for multiple myeloma, opening up a growing new market that some analysts expect to make a meaningful contribution to the thalidomide derivative's global sales over the longer term.